Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Stage III recurrent Melanoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Stage III Melanoma That Cannot Be Removed By Surgery, Stage IV Melanoma, and Recurrent Melanoma

Broader topic: Melanoma

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
III
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Stage III Melanoma That Cannot Be Removed By Surgery, Stage IV Melanoma, and Recurrent Melanoma

    Study evidence for this setting

    10 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00441337 · Registry condition search · Scope: unclear

    A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

    6 outcome links · 4 safety-group records · 0 quality-of-life measures

    →

    NCT01037790 · Registry condition search · Scope: unclear

    Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

    1 outcome links · 5 safety-group records · 0 quality-of-life measures

    →

    NCT01274338 · Source cited / selected · Scope: unclear

    Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

    6 outcome links · 6 safety-group records · 3 quality-of-life measures

    →

    NCT01769222 · Registry condition search · Scope: unclear

    Ipilimumab and Local Radiation for Selected Solid Tumors

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT02224781 · Source cited / selected · Scope: unclear

    Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Mel

    6 outcome links · 4 safety-group records · 0 quality-of-life measures

    →

    NCT02595866 · Registry condition search · Scope: unclear

    Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

    6 outcome links · 5 safety-group records · 0 quality-of-life measures

    →

    NCT03154190 · Registry condition search · Scope: unclear

    Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT04099251 · Source cited / selected · Scope: unclear

    Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

    6 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT04514484 · Registry condition search · Scope: unclear

    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT04985604 · Registry condition search · Scope: unclear

    Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice